Committee For Science, Innovation And Industry (CSII)
The CSII is composed of qualified persons with particular competencies in Genopole’s fields of activity. Its members are approved by the General Meeting. The role of the CSII is to provide the General Meeting with opinions and recommendations on the scientific and industrial orientations of GIP Genopole. A seat on the CSII is accorded intuiti personae and the members act in strict independence of their affiliations.
CSII President
Emmanuelle QUILES
Emmanuelle’s current global role at Janssen is to focus on maximizing the value of its pipeline and innovation in 3 therapeutic areas, working closely with R&D. From 2015 to 2021, as Managing Director, she championed the transformation of Janssen France implementing ambitious innovative programs, where she fostered talent development and accelerated employee use of digital solutions for patients’ benefit. She was involved in multiple forums in healthcare innovation where she strongly supported collaborations between private and public healthcare decision makers and supported the innovation ecosystem with a focus on Artificial Intelligence. Before that, she held various positions of increasing responsibility in R&D, commercial and management in linternational pharmaceutical companies and biotech. She is a board member of Business France.
CSII Members
- Florence Agostino-Etchetto, CEO – Lyonbiopole
- Emmanuel Barillot, Team Leader – Institut Curie
- Nadine Bongaerts-Duportet, Administrative Board Member – Hello Tomorrow
- Fayza Daboussi, Director of Life Sciences – Toulouse White Biotechnology
- Olivier Dugas, Deputy Technical Lead, Precision Farming – Limagrain
- Marco Fiorini, General Manager, IA & Cancer Group – PariSanté Campus
- Philippe Gesnouin, EIT Digital & EIT Health Project Officer – Inrae
- Xavier Gidrol, Director of the Large Scale Biology laboratory and the Biomics laboratory – CEA
- David Guerrand, Biotech Business Director – Lallemand
- Christophe Junot, Research Director – CEA
- Philippe Lavocat, Chief Executive Officer – GENCI
- Franck Molina, Director of Public-Private Research Center – SyséDiag (CNRS-Alcediag)
- Sylvie Ponchaut, Managing Director – BioWin
- Eric Quemeneur, Executive Vice President and R&D Vice President – Transgene SA
- Emmanuelle Quilès, Chief Executive Officer – Janssen France
- Sébastien Ribault, Vice-President – Merck Life Sciences
- Dominique Stoppa-Lyonnet, Professor of Genetics, Paris-Descartes University, and Head of Genetics – Institut Curie
